# Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

> **NCT03547700** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Lymphoma, T-Cell, Peripheral

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT03547700
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-26
- **Primary completion:** 2020-08-27
- **Final completion:** 2020-08-27
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547700, "Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03547700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*